296 related articles for article (PubMed ID: 27027429)
1. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.
Misawa K; Mochizuki D; Imai A; Endo S; Mima M; Misawa Y; Kanazawa T; Carey TE; Mineta H
Oncotarget; 2016 May; 7(18):26087-98. PubMed ID: 27027429
[TBL] [Abstract][Full Text] [Related]
2. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
[TBL] [Abstract][Full Text] [Related]
3. The neuropeptide genes
Misawa K; Mima M; Imai A; Mochizuki D; Misawa Y; Endo S; Ishikawa R; Kanazawa T; Mineta H
Clin Epigenetics; 2018; 10():52. PubMed ID: 29682090
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.
Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H
Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.
Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H
Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of collagen α2 (I) gene (COL1A2) is an independent predictor of survival in head and neck cancer.
Misawa K; Kanazawa T; Misawa Y; Imai A; Endo S; Hakamada K; Mineta H
Cancer Biomark; 2011-2012; 10(3-4):135-44. PubMed ID: 22674299
[TBL] [Abstract][Full Text] [Related]
8. Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer.
Misawa K; Kanazawa T; Misawa Y; Imai A; Uehara T; Mochizuki D; Endo S; Takahashi G; Mineta H
J Cancer Res Clin Oncol; 2013 May; 139(5):879-89. PubMed ID: 23420374
[TBL] [Abstract][Full Text] [Related]
9. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance.
Carvalho AL; Henrique R; Jeronimo C; Nayak CS; Reddy AN; Hoque MO; Chang S; Brait M; Jiang WW; Kim MM; Claybourne Q; Goldenberg D; Khan Z; Khan T; Westra WH; Sidransky D; Koch W; Califano JA
Clin Cancer Res; 2011 Jul; 17(14):4782-9. PubMed ID: 21628494
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic inactivation of galanin receptor 1 in head and neck cancer.
Misawa K; Ueda Y; Kanazawa T; Misawa Y; Jang I; Brenner JC; Ogawa T; Takebayashi S; Grenman RA; Herman JG; Mineta H; Carey TE
Clin Cancer Res; 2008 Dec; 14(23):7604-13. PubMed ID: 19047085
[TBL] [Abstract][Full Text] [Related]
11. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
12. Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma.
Steinmann K; Sandner A; Schagdarsurengin U; Dammann RH
Oncol Rep; 2009 Dec; 22(6):1519-26. PubMed ID: 19885608
[TBL] [Abstract][Full Text] [Related]
13.
Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; Franzen A; Dietrich J; Kristiansen G; Bootz F; Schröck A; Dietrich D
Clin Epigenetics; 2017; 9():12. PubMed ID: 28174607
[TBL] [Abstract][Full Text] [Related]
14. Patterns of gene promoter methylation in squamous cell cancer of the head and neck.
Hasegawa M; Nelson HH; Peters E; Ringstrom E; Posner M; Kelsey KT
Oncogene; 2002 Jun; 21(27):4231-6. PubMed ID: 12082610
[TBL] [Abstract][Full Text] [Related]
15. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer.
Sun W; Zaboli D; Wang H; Liu Y; Arnaoutakis D; Khan T; Khan Z; Koch WM; Califano JA
Clin Cancer Res; 2012 Feb; 18(4):1082-91. PubMed ID: 22228635
[TBL] [Abstract][Full Text] [Related]
16. Comparison of promoter hypermethylation pattern in salivary rinses collected with and without an exfoliating brush from patients with HNSCC.
Sun W; Zaboli D; Liu Y; Arnaoutakis D; Khan T; Wang H; Koch W; Khan Z; Califano JA
PLoS One; 2012; 7(3):e33642. PubMed ID: 22438973
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of TIMP3 hypermethylation in post-treatment salivary rinse from head and neck squamous cell carcinoma patients.
Rettori MM; de Carvalho AC; Bomfim Longo AL; de Oliveira CZ; Kowalski LP; Carvalho AL; Vettore AL
Carcinogenesis; 2013 Jan; 34(1):20-7. PubMed ID: 23042095
[TBL] [Abstract][Full Text] [Related]
18. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J
Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
[TBL] [Abstract][Full Text] [Related]
19. The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases.
Ai L; Stephenson KK; Ling W; Zuo C; Mukunyadzi P; Suen JY; Hanna E; Fan CY
Mod Pathol; 2003 Sep; 16(9):944-50. PubMed ID: 13679459
[TBL] [Abstract][Full Text] [Related]
20. DNA content and methylation of p16, DAPK and RASSF1A gene in tumour and distant, normal mucosal tissue of head and neck squamous cell carcinoma patients.
Laytragoon-Lewin N; Chen F; Castro J; Elmberger G; Rutqvist LE; Lewin F; Turesson I; Lundgren J
Anticancer Res; 2010 Nov; 30(11):4643-8. PubMed ID: 21115918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
